Drugs / 4SCAR19
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04429438 | Jun 2026 → Dec 2029 expected | B-cell neoplasm | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03125577 | Aug 2025 → Dec 2028 expected | B-cell neoplasm | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03050190 | May 2025 → Sep 2028 expected | B-cell neoplasm | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4SCAR19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03125577 ↗ |
| Modality | Cell therapy | “a 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 (4SCAR19)” NCT03050190 ↗ |
| Target | CD19 | “targeting CD19 (4SCAR19)” NCT03050190 ↗ |